Merck KGA acquires HUB Organoids holding: expansion of its next-gen biology portfolio

21 januari 2025
The Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, acquired HUB Organoids Holding B.V., Utrecht, the Netherlands, on December 23, 2024. The acquisition is a strategic step aligned with the company’s commitment to providing novel next-generation biology solutions to the life science industry. Access to HUB's technology enables faster and more effective drug development. Terms of the deal were not disclosed.

“The use of organoids offers tremendous potential to improve the drug discovery process,” said Jean-Charles Wirth, Head of Science & Lab Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany. “HUB’s advanced technology, combined with our cell culture expertise and broad portfolio, makes us a valuable resource for researchers looking to leverage the power of 3D cell culture to understand the impact of drug response earlier in the development process.”

HUB possesses the foundational patent portfolio on organoids and a robust service offering ranging from new model generation to assay development and high-throughput screening, enhancing Merck KGaA, Darmstadt, Germany´s offering of cell culture tools to academia, biotech, and pharma customers. The team of approximately 70 employees celebrated the acquisition together at the HUB campus in Utrecht, Netherlands.

Bron: HUB Organoids Holding B.V.

Altijd op de hoogte blijven?